![Nicole Kuderer: Glad we finally realize that pCR is not a valid trial surrogate for OS/DFS](https://oncodaily.com/pub/uploads/2024/06/1517476934073-e1719239295190.png)
Photo from Nicole Kuderer/LinkedIn
Jul 1, 2024, 12:09
Nicole Kuderer: Glad we finally realize that pCR is not a valid trial surrogate for OS/DFS
Nicole Kuderer, medical oncologist at the Division of Hematology of the University of Washington Medical Center, shared on X/Twitter:
“Glad we finally realize the serious adverse effects of ignoring that pCR is not a valid trial surrogate for OS/DFS (when a SOC drug exists)
We with Bad Venezolano 2018 to add other key progn factors.
The restricted mean survival time (RMST) is a robust alternative (but still underestimates also?) and performs much better w scenarios w late separation of survival curves.
We highlighted in our Bad Venezolano article on novel challenges with FDA approvals.”
Source: Nicole Kuderer/X
Aug 10, 2024, 19:12